Nicolas Fischer - CEO
After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry).
Nicolas Fischer - CEO
After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.
At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience.
Oliver Eckelmann - CFO
Since mid-2019 he serves as the COO and CFO of Light Chain Bioscience – NovImmune SA.
Oliver Eckelmann - COO
Since mid-2019 he serves as the COO and CFO of Light Chain Bioscience – NovImmune SA.
Oliver joined the Pharmaceutical company Roche in the beginning of 2006 and has held positions of increasing responsibility in controlling and planning. In 2009 he was appointed as Roche’s VP/Global Head of Strategy, Planning and Special Projects in Basel, Switzerland. In September 2012 he took over the role as CFO and Deputy CEO for Roche in Australia.
At the beginning of his career, he has held positions with consultancy firms Booz & company and Roland Berger Strategy Consultants.
Oliver holds a PhD in economics.
Walter Ferlin - CSO
Born in Australia, Walter went on to obtain his PhD in Immunology at the University of California, Davis and the DNAX Research Institute in Palo Alto, California.
Walter Ferlin - CSO
Born in Australia, Walter went on to obtain his PhD in Immunology at the University of California, Davis and the DNAX Research Institute in Palo Alto, California.
In 2003, Walter joined Novimmune as the leader of the anti-interferon gamma antibody program (NI-0501) which in 2018 became Novimmune’s first approved drug and the first and only treatment for primary Hemophagocytic lymphohistiocytosis.
Walter has led the preclinical and translational sciences team for the development of monoclonal antibodies and, more recently, bispecific antibodies in the field of immuno-oncology.
Jose Saro - CMO
Jose has over 25 years of experience in the preclinical, translational and clinical development of oncology compounds.
Jose Saro - Chief Medical Officer
Jose has over 25 years of experience in the preclinical, translational and clinical development of oncology compounds. Throughout his career, he has developed an extensive global network among oncologic academic institutions and the pharmaceutical industry.
Jose joined Light Chain Bioscience – NovImmune SA as CMO in May 2023, his previous position was at Adaptimmune Therapeutics, as Vice-President global Medical Development, leading the clinical development of Adaptimmune’s cell therapy pipeline.
Previously, he led the ceralasertib post-PARP inhibitor early clinical development program in solid tumors at AstraZeneca. Prior to that, he worked at Avacta as Chief Medical Officer driving the development strategy of Affimer® programs into the clinic. Before Avacta, Dr. Saro served as Senior Translational Medicine Leader at Roche where he ran three global immunotherapy programs – a targeted cytokine, and two T-cell bispecific antibodies in solid tumors – in collaboration with top academic institutions in the EU and US. Previously, he led global clinical programs at Bristol Myers Squibb including dasatinib, ipilimumab (anti-CTLA4), nivolumab (anti-PD1), anti-PDL1, anti-KIR, anti-LAG3, brivanib, a MEK inhibitor, and elotuzumab. While at Novartis he focused on biomarkers in the preclinical and clinical settings. Dr. Saro earned a medical degree from the University of Oviedo, Spain and a master’s degree in pharmaceutical medicine from Complutense University of Madrid, Spain.
Krzysztof Masternak - Director Discovery
After obtaining a PhD in molecular virology at the University of Lausanne, Krzysztof worked for several year on gene expression regulation at the University of Geneva Medical School.
Krzysztof Masternak - Director of Discovery
After obtaining a PhD in molecular virology at the University of Lausanne, Krzysztof worked for several year on gene expression regulation at the University of Geneva Medical School. He joined Novimmune in 2002, where he led several discovery programs to clinical ready stage.
As head of biology at Novimmune, Krzysztof was responsible for pioneering therapeutic CD47 dual targeting programs on the bispecific antibody platform.
Now as Director of Therapeutic Programs at Light Chain Bioscience, he drives the development of novel bispecific antibodies.
Limin Shang - Director Pharmacology
After obtaining a PhD in pharmacology from SUNY Buffalo State, Buffalo, NY, Limin worked on animal disease models for several years at the Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY.
Limin Shang - Director of Pharmacology
After obtaining a PhD in pharmacology from SUNY Buffalo State, Buffalo, NY, Limin worked on animal disease models for several years at the Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY.
At Novimmune since 2009, he was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.
Valerie Callou - Director Finance & HR
After 15 years in finance and controlling positions for a French retail company to support the development of its international activities, Valérie moved to Switzerland in 2008.
Callou Valerie - Director of Finance & HR
After 15 years in finance and controlling positions for a French retail company to support the development of its international activities, Valérie moved to Switzerland in 2008.
Since then, she has worked for biotech companies with finance and HR roles.
In 2019, Valérie joined Light Chain Bioscience to support finance, HR and administrative activities such as logistic.
